Published by ETHealthworld.com on February 24, 2016 By Dr. Mandar Kulkarni, Chief Technology Officer, Cancer Genetics India Reforms of the last budget continue to stabilize and grow the Indian economy. Most analysts and leading indices have a positive outlook on economic growth in India.On the back of a 2014-15 budget that focused on middle class tax relief, […]
Published in “iCommunity Newsletter” by Illumina on February 2016 Next-generation sequencing has the potential to open new doors for detecting blood cancers. Introduction Blood cancers affect over 1 million people in the United States alone.1 Early detection is critical for any type of cancer, but many blood disorders—such as leukemia, lymphoma, and myeloma—can be hard to […]
Published on Immuno-Oncology News on January 29, 2016 by Charles Moore High-tech tests designed to measure IO markers and determine patient suitability for clinical trials Cancer Genetics, Inc., (CGI), a biotech firm focused on the emerging fields of personalized medicine and immuno-oncology, reports the launch of its portfolio of comprehensive new tests and technologies to help […]
Published on The Pharma Times on August 27, 2015 What is genetics and how does it influence cancer? The human body packs in approximately 100 trillion cells that are carefully coordinated for optimized functioning, including voluntary and involuntary actions. Each cell is constructed with a few distinct classes of macromolecular building blocks (e.g. proteins, carbohydrates, nucleic […]
By: Mandar Kulkarni, Chief Technology Officer, Cancer Genetics India Published on Healthcare Executive on August 13, 2015 The human body packs in approximately 100 trillion cells that are carefully coordinated for optimized functioning, including voluntary and involuntary actions. Each cell is constructed with a few distinct classes of macromolecular building blocks (e.g. proteins, carbohydrates, nucleic […]
Over 370,000 patients in India develop solid tumour based cancers annually, that require comprehensive genomic profiling. Cancer Genetics India launched a solid tumour Hotspot panel based on Next generation sequencing for its biopharma and clinical customers throughout Asia a few months ago. Shalini Gupta finds out more about the company’s plans in an interview with Panna Sharma, President and Chief Executive Officer, Cancer Genetics Inc.
By Eric Strauss, May 26, 2015 at 10:06 AM A Rutherford-based cancer diagnostics company has been chosen by a Japanese medical firm to provide next-generation gene sequencing services, it announced Monday. Read more in NJBiz.
Today CGI is joining people around the world in observance of World Cancer Day. World Cancer Day marks an opportunity for us as a company to reflect on the progress we are making in the fight against cancer, and also to consider the tremendous needs that still exist.
Gentris is a market leader in providing pharmacogenomics, genotyping, and biorepository services to the pharmaceutical and biotech industries. Gentris advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly and improving patient care.
“There’s an emerging market of patients and clinicians who want diagnostic content that complies with the same standards of US healthcare companies,” says Sharma. “Growth is also driven in large part by an increase in public health spending and as cancer incidence increases, so too has spending on research in these areas. Patients and clinicians, as well as research organisations, need clinically validated tests that will work for India’s populations.”
As newer therapies for cancer hit the market, there’s a silent churn going on as diagnostic companies prepare for the future by stepping into unchartered territories.
In the nearly forty years that LDTs have enjoyed this policy of “enforcement discretion,” they have grown from a small but vital niche used mainly by hospital labs to diagnose rare diseases, to an industry where big players like Myriad Genetics and Genomic Health can post profits in the hundreds of millions of dollars.
Employees at Cancer Genetics, Inc., are on the cutting edge of developing cancer tests, and many employees have personal stories of their own cancers and those of family members who have battled the cancers the company addresses.
By Jane Houldsworth, PhD, Special to Everyday Health Article originally published by Everyday Health. As my biomedical career developed in the field of cancer research, I never considered the possibility of my work benefiting myself. Over the years, I had focused my studies on the genetics and biology of lymphoma and testicular cancer, but never planned […]
In March, CGI marked Kidney Cancer Awareness Month with a live-tweet event #KidneyLive. We followed Lonnie around the lab as she performed a UroGenRA-Kidney test – CGI’s proprietary test that can diagnose and sub-type kidney tumors!
As CEO of Cancer Genetics (CGIX), Panna Sharma was attracted to the emerging leader in DNA-based cancer diagnostics and services by its rich heritage in understanding genetic changes and aberrations that have clinical value.
Panna Sharma, CEO of Rutherford, N.J.-based Cancer Genetics, Inc. (OTCQB: CGIX), talks with the Opportunist’s Managing Editor Leslie Stone about his company’s role in DNA-based cancer diagnostics and its mission to improve the success rate in cancer treatment.
Cancer Genetics’ wholly-owned subsidiary, Cancer Genetics Italia, has entered into an agreement with Excilone for the distribution of CGI Italia’s oncology-focused fluorescence in situ hybridization (“FISH”) Probes.
CGI subsidiary, Cancer Genetics Italia, has entered into an agreement with Nikon Instruments for the distribution of oncology-focused DNA Probes intended for fluorescence in situ hybridization (“FISH”) in the Italian market.
UroGenRA™-Kidney was designed and developed at Cancer Genetics to assist in the diagnosis and treatment selection of kidney cancer. Clinical Laboratory Improvement Amendments (CLIA) & New York State approvals of the microarray as a laboratory developed test (LDT) expand CGI’s menu of proprietary molecular diagnostic tests for urogenital and hematological cancers. Rutherford, May 2, […]